Last reviewed · How we verify
Abiraterone acetate standard dose
Inhibits CYP17, an enzyme involved in the production of androgens.
Inhibits CYP17, an enzyme involved in the production of androgens. Used for Prostate cancer.
At a glance
| Generic name | Abiraterone acetate standard dose |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | CYP17 inhibitor |
| Target | CYP17 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Abiraterone acetate is a CYP17 inhibitor that blocks the production of androgens, such as testosterone, which are involved in the growth and spread of prostate cancer cells.
Approved indications
- Prostate cancer
Common side effects
- Fatigue
- Hypertension
- Diarrhea
Key clinical trials
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer (PHASE1, PHASE2)
- RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer) (PHASE4)
- A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder (PHASE2)
- Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer (EARLY_PHASE1)
- Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone (PHASE2)
- Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer (PHASE2)
- Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: